- Recordati’s Revenue: Preliminary revenue for the first quarter of 2025 surpassed estimates, reaching €680 million compared to the estimated €657 million.
- Future Revenue Targets: By 2027, Recordati aims to achieve net revenue between €3 billion and €3.2 billion.
- EBITDA Goals: The company has set EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) targets ranging from €1.14 billion to €1.225 billion for 2027.
- Adjusted Net Income Projection: Recordati’s projected adjusted net income for 2027 is between €770 million and €820 million.
- Market Analyst Recommendations: The company’s stock presently has 5 buy, 6 hold, and 1 sell ratings from analysts.
A look at Recordati SpA Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 3 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Recordati SpA, a pharmaceutical company, shows a promising long-term outlook according to Smartkarma Smart Scores. The company scores moderately in Value, Dividend, Growth, Resilience, and notably strong in Momentum. This indicates a favorable overall outlook for Recordati SpA, with particular strengths in its momentum which can drive future performance.
Recordati SpA, known for manufacturing pharmaceuticals globally, holds scores that suggest a stable and growing future. With a balanced scoring across various factors, including dividend and growth potential, the company is positioned well for sustained success. Additionally, its strong momentum score implies a positive market perception and potential for continued upward movement in the future.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
